Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HERNAN A SALAZAR

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1538220892
CMS profile
919244
Location
SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$397.53

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $265.94 2
Food and Beverage $131.59 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
Novartis Pharmaceuticals Corporation $397.53 3

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HERNAN A SALAZAR

NPI 1538220892 · CMS profile ID 919244

Allopathic & Osteopathic Physicians / Internal Medicine

SAN ANTONIO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1538220892?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HERNAN A SALAZAR, NPI 1538220892, CMS profile ID 919244. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1538220892?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). HERNAN A SALAZAR, NPI 1538220892, CMS profile ID 919244. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1538220892?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
HERNAN A SALAZAR, NPI 1538220892, CMS profile ID 919244, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1538220892?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $397.53 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $225.9401/14/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726112951 CMS
Novartis Pharmaceuticals Corporation $40.0001/14/2020 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726112953 CMS
Novartis Pharmaceuticals Corporation $131.5901/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726112957 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $713.29 23
PY2020 $397.53 3
PY2023 $727.75 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2023
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2023
Generated from
OP_DTL_GNRL_PGYR2023_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $189,942.29 38
PY2024 Principal investigator $116,310.00 16
PY2023 Recipient $291.00 1
PY2023 Principal investigator $1,683,804.34 55
PY2022 Recipient $1,491.00 2
PY2022 Principal investigator $4,307,067.33 117
PY2021 Recipient $201.98 1
PY2021 Principal investigator $8,685,200.41 155
PY2020 Recipient $145.50 1
PY2020 Principal investigator $2,390,117.44 47
PY2019 Recipient $705.39 1
PY2019 Principal investigator $1,142,050.05 20

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

156 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $15,072.00 12/28/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787660585
Principal investigator 1 Innocoll Incorporated $10,000.00 12/22/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty No dispute reported 06/30/2026 808594457
Principal investigator 1 Innocoll Incorporated $3,453.60 12/22/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty No dispute reported 06/30/2026 808594459
Principal investigator 1 Innocoll Incorporated $3,000.00 12/22/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty No dispute reported 06/30/2026 808594461
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $7,500.00 12/22/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMIZED DOUBLE-BLIND, DOUBLE-DUMMY, PROOF OF CONCEPT PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-951 VERSUS ONDANSETRON IN THE PROPHYLAXIS OF POSTOPERATIVE NAUSEA AND VOMITING IN HIGH-RISK SUBJECTS No dispute reported 06/30/2026 816789525
Recipient Eli Lilly and Company $201.98 12/14/2021 Covered Recipient Physician A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 819444243
Principal investigator 1 Endo Pharmaceuticals Inc. $3,500.00 12/14/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830765913
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,640.00 12/13/2021 Non-covered Recipient Entity
ERG Holding Company LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417743
Principal investigator 1 Alnylam Pharmaceuticals Inc. $203.00 12/13/2021 Non-covered Recipient Entity
ERG Holding Company LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417745
Principal investigator 1 Alnylam Pharmaceuticals Inc. $76.00 12/13/2021 Non-covered Recipient Entity
ERG Holding Company LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417747
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,000.00 12/13/2021 Non-covered Recipient Entity
ERG Holding Company LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417749
Principal investigator 1 Alnylam Pharmaceuticals Inc. $364.50 12/13/2021 Non-covered Recipient Entity
ERG Holding Company LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417751
Principal investigator 1 Alnylam Pharmaceuticals Inc. $21.00 12/13/2021 Non-covered Recipient Entity
ERG Holding Company LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417753
Principal investigator 1 Janssen Research & Development, LLC $339.00 12/13/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787660429
Principal investigator 1 Janssen Research & Development, LLC $525.00 12/13/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787660461
Principal investigator 1 Janssen Research & Development, LLC $6,479.00 12/13/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787660513
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,750.00 12/08/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A RANDOMIZED DOUBLE-BLIND, DOUBLE-DUMMY, PROOF OF CONCEPT PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-951 VERSUS ONDANSETRON IN THE PROPHYLAXIS OF POSTOPERATIVE NAUSEA AND VOMITING IN HIGH-RISK SUBJECTS No dispute reported 06/30/2026 816783353
Principal investigator 1 DEXCOM, INC. $50,000.00 12/07/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINIOUS GLUCOSE MONITORING (CGM) SYSTEM (G7PIV#2) No dispute reported 06/30/2026 845257467
Principal investigator 1 AstraZeneca UK Limited $3,629.12 12/02/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
AZD2693, Cardiovascular, Renal and Metabolism No dispute reported 06/30/2026 826499735
Principal investigator 1 PFIZER INC. $4,207.25 11/30/2021 Non-covered Recipient Entity
ERG Holding Company LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832839129
Principal investigator 1 Innocoll Incorporated $55,651.20 11/26/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty No dispute reported 06/30/2026 808594425
Principal investigator 1 Innocoll Incorporated $3,412.80 11/26/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty No dispute reported 06/30/2026 808594427
Principal investigator 1 Janssen Research & Development, LLC $13,505.00 11/19/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787660565
Principal investigator 1 Heron Therapeutics, Inc. $9,000.00 11/18/2021 Non-covered Recipient Entity
ERG Holding Company LLC
A Multi-surgery Assessment of ZYNRELEF (HTX-011), AMAZE No dispute reported 06/30/2026 782090963
Principal investigator 1 Endo Pharmaceuticals Inc. $1,093.75 11/16/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830765875
Principal investigator 1 Endo Pharmaceuticals Inc. $6,655.00 11/16/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830765885
Principal investigator 1 Endo Pharmaceuticals Inc. $9,125.00 11/16/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830765893
Principal investigator 1 Endo Pharmaceuticals Inc. $6,144.00 11/16/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830765901
Principal investigator 1 PFIZER INC. $15,000.00 11/16/2021 Non-covered Recipient Entity
ERG Holding Company LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832631169
Principal investigator 1 PFIZER INC. $20,335.20 11/16/2021 Non-covered Recipient Entity
ERG Holding Company LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832799311
Principal investigator 1 Siemens Medical Solutions USA, Inc. $47,356.00 11/12/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL
Not supplied No dispute reported 06/30/2026 768161360
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $379.77 11/10/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 816775087
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $15,500.00 11/10/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
HEALTHY VOLUNTEERS ANESTHETIZED STUDY WITH TAK-925 FOR POST OP RECOVERY No dispute reported 06/30/2026 816775097
Principal investigator 1 Siemens Medical Solutions USA, Inc. $7,601.32 11/05/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL
Not supplied No dispute reported 06/30/2026 768161466
Principal investigator 1 Alnylam Pharmaceuticals Inc. $10,000.00 11/03/2021 Non-covered Recipient Entity
ERG Holding Company LLC
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417733
Principal investigator 1 Janssen Research & Development, LLC $50.00 11/03/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787660393
Principal investigator 1 Janssen Research & Development, LLC $220.00 11/03/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787660413
Principal investigator 1 Janssen Research & Development, LLC $510.00 11/03/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787660447
Principal investigator 1 Janssen Research & Development, LLC $1,400.00 11/03/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787660481
Principal investigator 1 Janssen Research & Development, LLC $6,270.00 11/03/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787660497
Principal investigator 1 Janssen Research & Development, LLC $8,649.00 11/03/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787660529
Principal investigator 1 Janssen Research & Development, LLC $10,850.00 11/03/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787660549
Principal investigator 1 PFIZER INC. $11,500.00 11/02/2021 Non-covered Recipient Entity
ERG Holding Company LLC
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832631159
Principal investigator 1 Eli Lilly and Company $312,478.80 11/01/2021 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
A MULTIPLE-DOSE STUDY IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS,AND PHARMACODYNAMICS OF LY3502970 No dispute reported 06/30/2026 819458403
Principal investigator 1 PFIZER INC. $9,969.75 10/29/2021 Non-covered Recipient Entity
ERG Holding Company LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832723789
Principal investigator 1 Innocoll Incorporated $1,082,916.00 10/25/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty No dispute reported 06/30/2026 808594397
Principal investigator 1 Innocoll Incorporated $11,902.80 10/25/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty No dispute reported 06/30/2026 808594399
Principal investigator 1 Innocoll Incorporated $102,220.80 10/25/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty No dispute reported 06/30/2026 808594401
Principal investigator 1 Janssen Research & Development, LLC $27,529.00 10/22/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787661021
Principal investigator 1 PFIZER INC. $11,500.00 10/13/2021 Non-covered Recipient Entity
ERG Holding Company LLC
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832773733
Principal investigator 1 DEXCOM, INC. $87,917.00 10/12/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM - (G7 PIVOTAL) No dispute reported 06/30/2026 845256977
Principal investigator 1 DEXCOM, INC. $6,000.00 10/12/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM - (G7 PIVOTAL) No dispute reported 06/30/2026 845256983
Principal investigator 1 DEXCOM, INC. $76,542.00 10/12/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM (BETA OH6) No dispute reported 06/30/2026 845256989
Principal investigator 1 DEXCOM, INC. $2,400.00 10/12/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM (BETA OH6) No dispute reported 06/30/2026 845256995
Principal investigator 1 Endo Pharmaceuticals Inc. $1,169.00 10/12/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830765863
Principal investigator 1 Vertex Pharmaceuticals Incorporated $163,624.28 10/07/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS
A Phase 2 randomized double blind placebo controlled study evaluating the efficacy and safety of VX-548 for acute pain after an abdominoplasty No dispute reported 06/30/2026 793097359
Principal investigator 1 Janssen Research & Development, LLC $6,479.00 10/06/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787660971
Principal investigator 1 Janssen Research & Development, LLC $9,588.00 10/06/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787660985
Principal investigator 1 Janssen Research & Development, LLC $14,350.00 10/06/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787661005
Principal investigator 1 Eli Lilly and Company $61,953.55 10/05/2021 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
A SINGLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3819469 No dispute reported 06/30/2026 819457565
Principal investigator 1 Janssen Research & Development, LLC $38,798.00 09/24/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659861
Principal investigator 1 Janssen Research & Development, LLC $80,813.00 09/22/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659877
Principal investigator 1 Janssen Research & Development, LLC $345.00 09/20/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Double Blind Placebo Controlled Randomized Multipart Single and Multiple Ascending Dose Study to Investigate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered JNJ75220795 No dispute reported 06/30/2026 787661223
Principal investigator 1 Janssen Research & Development, LLC $450.00 09/20/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Double Blind Placebo Controlled Randomized Multipart Single and Multiple Ascending Dose Study to Investigate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered JNJ75220795 No dispute reported 06/30/2026 787661243
Principal investigator 1 PFIZER INC. $920.00 09/20/2021 Non-covered Recipient Entity
ENDEAVOR CLNICAL TRIALS
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832604403
Principal investigator 1 PFIZER INC. $113.80 09/20/2021 Non-covered Recipient Entity
ENDEAVOR CLNICAL TRIALS
A PHASE 23 RANDOMIZED DOUBLEBLIND DOUBLEDUMMY PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332RITONAVIR IN PREVENTING SYMPTOMATIC SARSCOV2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID19 No dispute reported 06/30/2026 832604413
Principal investigator 1 Innocoll Incorporated $683,553.60 09/17/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty No dispute reported 06/30/2026 808594367
Principal investigator 1 Innocoll Incorporated $10,202.40 09/17/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty No dispute reported 06/30/2026 808594369
Principal investigator 1 Innocoll Incorporated $164,356.80 09/17/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty No dispute reported 06/30/2026 808594371
Principal investigator 1 Innocoll Incorporated $3,453.60 09/17/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty No dispute reported 06/30/2026 808594373
Principal investigator 1 Janssen Research & Development, LLC $43,160.00 09/17/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659811
Principal investigator 1 Endo Pharmaceuticals Inc. $2,900.00 09/14/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830765853
Principal investigator 1 DEXCOM, INC. $150,627.00 09/07/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM - (G7 PIVOTAL) No dispute reported 06/30/2026 845256621
Principal investigator 1 DEXCOM, INC. $32,568.00 09/07/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM - (G7 PIVOTAL) No dispute reported 06/30/2026 845256627
Principal investigator 1 Janssen Research & Development, LLC $450.00 08/27/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Double Blind Placebo Controlled Randomized Multipart Single and Multiple Ascending Dose Study to Investigate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered JNJ75220795 No dispute reported 06/30/2026 787661113
Principal investigator 1 Janssen Research & Development, LLC $550.00 08/27/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Double Blind Placebo Controlled Randomized Multipart Single and Multiple Ascending Dose Study to Investigate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered JNJ75220795 No dispute reported 06/30/2026 787661131
Principal investigator 1 Janssen Research & Development, LLC $2,595.00 08/27/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Double Blind Placebo Controlled Randomized Multipart Single and Multiple Ascending Dose Study to Investigate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered JNJ75220795 No dispute reported 06/30/2026 787661148
Principal investigator 1 Janssen Research & Development, LLC $1,500.00 08/27/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Double Blind Placebo Controlled Randomized Multipart Single and Multiple Ascending Dose Study to Investigate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered JNJ75220795 No dispute reported 06/30/2026 787661165
Principal investigator 1 Janssen Research & Development, LLC $690.00 08/27/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Double Blind Placebo Controlled Randomized Multipart Single and Multiple Ascending Dose Study to Investigate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered JNJ75220795 No dispute reported 06/30/2026 787661185
Principal investigator 1 Janssen Research & Development, LLC $435.00 08/27/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Double Blind Placebo Controlled Randomized Multipart Single and Multiple Ascending Dose Study to Investigate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered JNJ75220795 No dispute reported 06/30/2026 787661203
Principal investigator 1 Janssen Research & Development, LLC $102,501.00 08/25/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659845
Principal investigator 1 Janssen Research & Development, LLC $15,000.00 08/23/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659829
Principal investigator 1 DEXCOM, INC. $9,700.00 08/17/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM (BETA OH6) No dispute reported 06/30/2026 845256471
Principal investigator 1 PFIZER INC. $917.00 08/11/2021 Non-covered Recipient Entity
ENDEAVOR CLNICAL TRIALS
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 23 DOUBLEBLIND 2ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF07321332RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID19 WHO ARE AT INCREASED RISK OF PROGRESSING TO SEVERE ILLNESS No dispute reported 06/30/2026 832880551
Principal investigator 1 DEXCOM, INC. $20,200.00 08/10/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM - (G7 PIVOTAL) No dispute reported 06/30/2026 845256359
Principal investigator 1 Janssen Research & Development, LLC $40,349.00 08/09/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659747
Principal investigator 1 DEXCOM, INC. $33,004.00 08/03/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM - (G7 PIVOTAL) No dispute reported 06/30/2026 845256285
Principal investigator 1 Allergan, Inc. $9,000.00 08/02/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789019979
Principal investigator 1 Allergan, Inc. $500.00 08/02/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789019981
Principal investigator 1 Innocoll Incorporated $916,884.00 07/29/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty No dispute reported 06/30/2026 808594327
Principal investigator 1 Innocoll Incorporated $8,502.00 07/29/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty No dispute reported 06/30/2026 808594329
Principal investigator 1 Innocoll Incorporated $7,000.00 07/29/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty No dispute reported 06/30/2026 808594331
Principal investigator 1 Innocoll Incorporated $7,000.00 07/29/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty No dispute reported 06/30/2026 808594335
Principal investigator 1 Innocoll Incorporated $62,736.00 07/29/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty No dispute reported 06/30/2026 808594337
Principal investigator 1 Innocoll Incorporated $1,726.80 07/29/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty No dispute reported 06/30/2026 808594339
Principal investigator 1 Innocoll Incorporated $7,500.00 07/29/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of a 300-mg Dose of the INL-001 (Bupivacaine Hydrochloride) Implant in Patients Undergoing Abdominoplasty No dispute reported 06/30/2026 808594341
Principal investigator 1 Innocoll Incorporated $7,500.00 07/29/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-label Study to Evaluate the Safety and Pharmacokinetics of the INL-001 (Bupivacaine Hydrochloride) Implant in Adults Following Various Open Soft-Tissue Surgeries: Open Ventral Hernia Repair, Abdominoplasty, Open Abdominal Hysterectomy, Laparoscopic-assisted Colectomy, and Reduction Mammoplasty No dispute reported 06/30/2026 808594343
Principal investigator 1 Janssen Research & Development, LLC $64,144.00 07/23/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659765
Principal investigator 1 DEXCOM, INC. $24,854.00 07/20/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM (BETA OH6) No dispute reported 06/30/2026 845256223
Principal investigator 1 Janssen Research & Development, LLC $78,226.00 07/14/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659779
Principal investigator 1 Janssen Research & Development, LLC $36,395.00 07/02/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659797
Principal investigator 1 Janssen Research & Development, LLC $49,938.00 06/25/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659622
Principal investigator 1 Allergan, Inc. $4,386.25 06/24/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789019977
Principal investigator 1 Eli Lilly and Company $4,783.92 06/24/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS PA
A SINGLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3819469 No dispute reported 06/30/2026 819456945
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,000.00 06/23/2021 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417679
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,500.00 06/23/2021 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417681
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,000.00 06/23/2021 Non-covered Recipient Entity
ERG Holding Company LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828417683
Principal investigator 1 Janssen Research & Development, LLC $396,404.83 06/21/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Double Blind Placebo Controlled Randomized Multipart Single and Multiple Ascending Dose Study to Investigate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered JNJ75220795 No dispute reported 06/30/2026 787661077
Principal investigator 1 Janssen Research & Development, LLC $554,966.75 06/21/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC
A Double Blind Placebo Controlled Randomized Multipart Single and Multiple Ascending Dose Study to Investigate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered JNJ75220795 No dispute reported 06/30/2026 787661097
Principal investigator 1 Amgen Inc. $16,675.00 05/26/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS
AMG 609_ Ph1 Study To Evalulate Safety; PK and PD in AMG 609 No dispute reported 06/30/2026 830980003
Principal investigator 1 Janssen Research & Development, LLC $36,015.00 05/25/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659605
Principal investigator 1 Endo Pharmaceuticals Inc. $2,250.00 05/18/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830765843
Principal investigator 1 Eli Lilly and Company $75.00 05/14/2021 Covered Recipient Teaching Hospital
PIEDMONT HOSPITAL INC.
A SINGLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3819469 No dispute reported 06/30/2026 819448775
Principal investigator 1 Eli Lilly and Company $100.00 05/14/2021 Covered Recipient Teaching Hospital
KFH-HAWAII
A SINGLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3819469 No dispute reported 06/30/2026 819448865
Principal investigator 1 Eli Lilly and Company $1,383.00 05/14/2021 Non-covered Recipient Entity
ACCURATE CLINICAL RESEARCH INC
A SINGLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3819469 No dispute reported 06/30/2026 819449813
Principal investigator 1 Eli Lilly and Company $175.00 05/14/2021 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A SINGLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3819469 No dispute reported 06/30/2026 819453293
Principal investigator 1 Eli Lilly and Company $25.00 05/14/2021 Non-covered Recipient Entity
SUNCOAST CLINICAL RESEARCH
A SINGLE-ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3819469 No dispute reported 06/30/2026 819466983
Principal investigator 1 Allergan, Inc. $101.75 05/01/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789019975
Principal investigator 1 Eli Lilly and Company $48.50 04/30/2021 Non-covered Recipient Entity
TRIANGLE ORTHOPAEDIC ASSOCIATES PA
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 819469921
Principal investigator 1 Janssen Research & Development, LLC $183,750.00 04/27/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659587
Principal investigator 1 Janssen Research & Development, LLC $19,652.00 04/19/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659571
Principal investigator 1 Janssen Research & Development, LLC $10,133.00 04/14/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659553
Principal investigator 1 Endo Pharmaceuticals Inc. $5,700.00 04/13/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830765833
Principal investigator 1 DEXCOM, INC. $1,030.00 04/06/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
YSI FEASIBILITY SESSION STUDY OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM IN ADULTS AND PEDIATRICS WITH DIABETES MELLITUS (A OH5 SLOPE RANGE) No dispute reported 06/30/2026 845255325
Principal investigator 1 DEXCOM, INC. $6,526.00 04/06/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
YSI FEASIBILITY SESSION STUDY OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM IN ADULTS AND PEDIATRICS WITH DIABETES MELLITUS (A OH5 SLOPE RANGE) No dispute reported 06/30/2026 845255330
Principal investigator 1 DEXCOM, INC. $46,616.00 04/06/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM (BETA OH5) No dispute reported 06/30/2026 845255335
Principal investigator 1 DEXCOM, INC. $130,316.00 04/06/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM GLUCOSE MONITORING (CGM) (G7 OUS) No dispute reported 06/30/2026 845255343
Principal investigator 1 Janssen Research & Development, LLC $492,439.00 03/24/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659406
Principal investigator 1 Amgen Inc. $7,583.99 03/19/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS
AMG 609_ Ph1 Study To Evalulate Safety; PK and PD in AMG 609 No dispute reported 06/30/2026 830980005
Principal investigator 1 Allergan, Inc. $1,290.10 03/17/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789019973
Principal investigator 1 Endo Pharmaceuticals Inc. $7,288.00 03/16/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830765823
Principal investigator 1 Alnylam Pharmaceuticals Inc. $75.00 03/15/2021 Non-covered Recipient Entity
Endeavor Clinical Trials, P.A.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828418685
Principal investigator 1 Alnylam Pharmaceuticals Inc. $55.00 03/15/2021 Non-covered Recipient Entity
Endeavor Clinical Trials, P.A.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828418687
Principal investigator 1 Alnylam Pharmaceuticals Inc. $35.00 03/15/2021 Non-covered Recipient Entity
Endeavor Clinical Trials, P.A.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828418689
Principal investigator 1 Alnylam Pharmaceuticals Inc. $17.00 03/15/2021 Non-covered Recipient Entity
Endeavor Clinical Trials, P.A.
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, 2-Part Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-HSD in Healthy Adult Subjects and Multiple Dose ALN-HSD in Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 828418691
Principal investigator 1 Eli Lilly and Company $382.73 03/03/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS PA
A MULTIPLE-DOSE STUDY IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS,AND PHARMACODYNAMICS OF LY3502970 No dispute reported 06/30/2026 819457171
Principal investigator 1 Janssen Research & Development, LLC $6,529.00 03/01/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659387
Principal investigator 1 Janssen Research & Development, LLC $424,849.00 02/23/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659369
Principal investigator 1 Allergan, Inc. $1,290.10 02/19/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789019971
Principal investigator 1 Siemens Medical Solutions USA, Inc. $15,300.00 02/17/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL
Not supplied No dispute reported 06/30/2026 768160726
Principal investigator 1 Endo Pharmaceuticals Inc. $7,050.00 02/16/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830765801
Principal investigator 1 Endo Pharmaceuticals Inc. $7,050.00 02/16/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830765811
Principal investigator 1 Siemens Medical Solutions USA, Inc. $4,000.00 02/16/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL
Not supplied No dispute reported 06/30/2026 768160628
Principal investigator 1 Siemens Medical Solutions USA, Inc. $172,767.30 02/16/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL
Not supplied No dispute reported 06/30/2026 768160728
Principal investigator 1 Siemens Medical Solutions USA, Inc. $19,250.00 02/16/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL
Not supplied No dispute reported 06/30/2026 768160730
Principal investigator 1 Siemens Medical Solutions USA, Inc. $25,050.00 02/16/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC MIDWEST CLINICAL RESEARCH CTR LL
Not supplied No dispute reported 06/30/2026 768160732
Principal investigator 1 Eli Lilly and Company $4,401.54 01/26/2021 Non-covered Recipient Entity
ERG HOLDING CO LLC DBA ST LOUIS CLINICAL TRIALS LLC
A MULTIPLE-DOSE STUDY IN PARTICIPANTS WITH TYPE 2 DIABETES MELLITUS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS,AND PHARMACODYNAMICS OF LY3502970 No dispute reported 06/30/2026 819457155
Principal investigator 1 Eli Lilly and Company $100,667.00 01/26/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS PA
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 819457553
Principal investigator 1 Janssen Research & Development, LLC $786,884.00 01/26/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659353
Principal investigator 1 Allergan, Inc. $4,369.05 01/25/2021 Non-covered Recipient Entity
ERG HOLDING COMPANY LLC DBA MIDWEST CLINICAL RESE
AURORA: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis No dispute reported 06/30/2026 789019969
Principal investigator 1 DEXCOM, INC. $23,522.00 01/20/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM - (ALGO) No dispute reported 06/30/2026 845254619
Principal investigator 1 Endo Pharmaceuticals Inc. $12,862.00 01/19/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
An Open-Label, Randomized, Parallel-Group, Three Treatment Arm, Multicenter Study on Hypogonadal Males to Evaluate the Effect on 24-Hour Ambulatory Blood Pressure After 16-Week Continuous Treatment with Marketed Testosterone Products No dispute reported 06/30/2026 830765793
Principal investigator 1 DEXCOM, INC. $25,000.00 01/12/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS LLC
EVALUATION OF THE SAFETY AND EFFECTIVENESS OF THE DEXCOM CONTINUOUS GLUCOSE MONITORING (CGM) SYSTEM - (G7 PIVOTAL) No dispute reported 06/30/2026 845254561
Principal investigator 1 Janssen Research & Development, LLC $4,866.00 01/12/2021 Non-covered Recipient Entity
Erg Holding Co. Llc
A Study of Ad26.COV2.S for the Prevention of SARSCoV2mediated COVID19 in Adults No dispute reported 06/30/2026 787659330
Principal investigator 1 Eli Lilly and Company $5,186.39 01/07/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS PA
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY COMPARING THE EFFICACY AND SAFETY OF TIRZEPATIDE VERSUS PLACEBO IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) No dispute reported 06/30/2026 819458733
Principal investigator 1 Novartis Pharmaceuticals Corporation $962.72 01/01/2021 Non-covered Recipient Entity
ENDEAVOR CLINICAL TRIALS
A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS EFFICACY, SAFETY, AND TOLERABILITY OF ORAL TROPIFEXOR (LJN452) & LICOGLIFLOZIN (LIK066) COMBINATION THERAPY, COMPARED TO EACH MONOTHERAPY, FOR TREATMENT OF ADULT PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND LIVER FIBROSIS No dispute reported 06/30/2026 800630775